#United States #Class Action #San Francisco #Aardvark Therapeutics #ARD-101

Aardvark Therapeutics Lawsuit Overview

In a significant move for investors, Hagens Berman Sobol Shapiro LLP has alerted shareholders of Aardvark Therapeutics, Inc. (NASDAQ: $AARD) about a class action lawsuit opportunity due to substantial losses incurred in recent times. Investors who purchased shares in connection with the company's IPO on February 13, 2025, and those who bought stocks between February 13, 2025, and May 14, 2026, now have a chance to take action before the lead plaintiff deadline of October 13, 2026.

Context of the Lawsuit

The complaint against Aardvark Therapeutics alleges that the company engaged in misleading practices regarding the safety and efficacy of their drug, ARD-101. This clinical-stage biopharmaceutical employer specializes in developing therapies aimed at treating disorders related to bitter taste receptor pathways, specifically targeting conditions like hyperphagia tied to Prader-Willi Syndrome (PWS).

In the detailed filing, it is stated that the company failed to disclose crucial information regarding ARD-101 which was reported to be less safe than previously indicated. Moreover, clinical trials revealed concerning cardiac observations during the testing phases. As a result, investor confidence was significantly shaken, drawing scrutiny over the company's clinical, regulatory, and commercial prospects.

Developments and Impact

On February 27, 2026, Aardvark announced a voluntary pause in its Phase 3 HERO trial due to the aforementioned safety issues. This revelation caused a plummet of over 56% in the company’s stock price. To compound this, the FDA later imposed a full clinical hold on the drug’s investigational new drug application on May 14, 2026, causing an additional decline of 32.1% in stock value.

These alarming developments have led to intensified investigations by legal authorities and have motivated researchers like Reed Kathrein from Hagens Berman to dig deeper into the allegations against Aardvark Therapeutics.

How Aardvark Investors Can Proceed

Investors who believe they fit the criteria to be class members have the right to apply to be appointed as Lead Plaintiff. This involves taking timely steps to ensure their voices are heard in the courtroom. Aardvark shareholders interested in pursuing this course of action should reach out to the firm for guidance on their legal rights and potential recovery options

Important Dates

• - Lead Plaintiff Deadline: October 13, 2026
• - Interested shareholders are encouraged to contact Hagens Berman at:

- Phone: 844-916-0895
- Email: [email protected]

Additionally, there is a whistleblower provision available for individuals with non-public information regarding Aardvark Therapeutics, allowing them a chance to aid in the investigation while potentially gaining rewards through the SEC Whistleblower program.

About Hagens Berman

Hagens Berman Sobol Shapiro LLP is known for its dedication to holding corporations accountable. The firm, based in San Francisco, focuses on complex litigation, representing investors, workers, consumers, and others affected by corporate malpractices. With a track record of securing $2.9 billion in claims, they have solidified their place as leaders in corporate accountability litigation.

For ongoing updates regarding the Aardvark investigation and other related news, shareholders can follow Hagens Berman on social media or visit their official website.

This lawsuit poses a crucial opportunity for investors to regain control and seek justice for the losses they have suffered, making it imperative to act before the approaching deadline.